The dismissal of Dr. Peter Marks from the Food and Drug Administration (FDA) by Robert F Kennedy Jr. has led to a significant decrease in the market value of major pharmaceutical companies, wiping out nearly £8bn. The exit of Dr. Marks raised concerns among investors resulting in a decrease in shares of Moderna, Pfizer, GSK, AstraZeneca, and several other companies. This decline was fueled by uncertainty over Trump's tariffs and concerns about Dr. Kennedy's anti-vaccine stance. Dr. Marks criticized Kennedy's misinformation about vaccine safety following his departure, highlighting the divergence in opinion between the two. Dr. Marks cautioned against undermining public confidence in well-established vaccines and expressed concerns about the direction the government was taking regarding vaccines. His resignation raised speculation about potential future challenges for global vaccine producers. Analysts noted that the departure of Dr. Marks could create near-term uncertainties in the industry, especially with regard to the development of biologics. The FDA has not yet announced a replacement for Dr. Marks, raising concerns about the possible alignment of the new appointee's views with those of Secretary Kennedy on vaccines.